+

WO2003042661A8 - Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer - Google Patents

Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer

Info

Publication number
WO2003042661A8
WO2003042661A8 PCT/US2002/036810 US0236810W WO03042661A8 WO 2003042661 A8 WO2003042661 A8 WO 2003042661A8 US 0236810 W US0236810 W US 0236810W WO 03042661 A8 WO03042661 A8 WO 03042661A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
diagnosis
compositions
modulators
Prior art date
Application number
PCT/US2002/036810
Other languages
English (en)
Other versions
WO2003042661A2 (fr
WO2003042661A3 (fr
Inventor
Daniel Afar
Natasha Aziz
Wendy M Ginsburg
Kurt C Gish
Richard Glynne
Peter A Hevezi
David H Mack
Richard Murray
Susan R Watson
Keith E Wilson
Albert Zlotnik
Original Assignee
Eos Biotechnology Inc
Daniel Afar
Natasha Aziz
Wendy M Ginsburg
Kurt C Gish
Richard Glynne
Peter A Hevezi
David H Mack
Richard Murray
Susan R Watson
Keith E Wilson
Albert Zlotnik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eos Biotechnology Inc, Daniel Afar, Natasha Aziz, Wendy M Ginsburg, Kurt C Gish, Richard Glynne, Peter A Hevezi, David H Mack, Richard Murray, Susan R Watson, Keith E Wilson, Albert Zlotnik filed Critical Eos Biotechnology Inc
Priority to CA002467433A priority Critical patent/CA2467433A1/fr
Priority to AU2002357734A priority patent/AU2002357734A1/en
Priority to JP2003544445A priority patent/JP2005525789A/ja
Priority to EP02792272A priority patent/EP1497454A2/fr
Publication of WO2003042661A2 publication Critical patent/WO2003042661A2/fr
Publication of WO2003042661A8 publication Critical patent/WO2003042661A8/fr
Publication of WO2003042661A3 publication Critical patent/WO2003042661A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des gènes dont l'expression est régulée positivement ou négativement dans certains cancers ou pathologies spécifiques, ou bien dont l'expression est régulée dans les états pathologiques. Sont également décrites des méthodes et des compositions connexes convenant pour le diagnostic, le pronostic et le traitement de ces pathologie ainsi que ces méthodes permettant d'identifier les modulateurs de ces dernières.
PCT/US2002/036810 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer WO2003042661A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002467433A CA2467433A1 (fr) 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
AU2002357734A AU2002357734A1 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
JP2003544445A JP2005525789A (ja) 2001-11-13 2002-11-13 ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
EP02792272A EP1497454A2 (fr) 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33246401P 2001-11-21 2001-11-21
US60/332,464 2001-11-21
US33439301P 2001-11-29 2001-11-29
US60/334,393 2001-11-29
US33539401P 2001-12-03 2001-12-03
US60/335,394 2001-12-03
US34037601P 2001-12-14 2001-12-14
US60/340,376 2001-12-14
US34721102P 2002-01-08 2002-01-08
US60/347,211 2002-01-08
US34734902P 2002-01-10 2002-01-10
US60/347,349 2002-01-10
US35525702P 2002-02-08 2002-02-08
US35525002P 2002-02-08 2002-02-08
US60/355,250 2002-02-08
US35671402P 2002-02-13 2002-02-13
US60/356,714 2002-02-13
US35907702P 2002-02-20 2002-02-20
US60/359,077 2002-02-20
US36880902P 2002-03-29 2002-03-29
US60/368,809 2002-03-29
US37011002P 2002-04-04 2002-04-04
US60/370,110 2002-04-04
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
US38661402P 2002-06-05 2002-06-05
US60/386,614 2002-06-05
US39683902P 2002-07-16 2002-07-16
US60/396,839 2002-07-16
US39784502P 2002-07-22 2002-07-22
US39777502P 2002-07-22 2002-07-22
US60/397,845 2002-07-22
US60/397,775 2002-07-22
US40945002P 2002-09-09 2002-09-09
US60/409,450 2002-09-09

Publications (3)

Publication Number Publication Date
WO2003042661A2 WO2003042661A2 (fr) 2003-05-22
WO2003042661A8 true WO2003042661A8 (fr) 2003-10-16
WO2003042661A3 WO2003042661A3 (fr) 2004-10-28

Family

ID=32097246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036810 WO2003042661A2 (fr) 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer

Country Status (1)

Country Link
WO (1) WO2003042661A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
JP2004500879A (ja) 2000-06-16 2004-01-15 バイオジェン　インコーポレイテッド 腎の調節エレメントおよびそれらの使用方法
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US20040110712A1 (en) * 2002-08-26 2004-06-10 Markowitz Sanford D. Methods for treating patients and identifying therapeutics
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
CA2448427C (fr) 2001-06-01 2013-09-24 Biogen, Inc. Molecules et procedes permettant d'empecher la liberation de kim-1
JP2005536439A (ja) 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
AU2003213672A1 (en) * 2002-03-04 2003-09-22 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
US20050014687A1 (en) * 2002-03-19 2005-01-20 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1534331B1 (fr) * 2002-06-21 2014-10-29 Johns Hopkins University School of Medicine Marqueurs de l'endothelium tumoral associe a une membrane
CA2492160A1 (fr) 2002-07-12 2004-01-22 The Johns Hopkins University Vaccins a la mesotheline et systemes de modele
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
DE60335636D1 (de) * 2002-09-11 2011-02-17 Genentech Inc Zusammensetzungen und verfahren für die tumordiagnose und behandlung
AU2003284891A1 (en) * 2002-10-23 2004-05-13 Ludwig Institute For Cancer Research A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
SI1585546T1 (sl) 2002-12-30 2008-12-31 Biogen Idec Inc KIM-1 antagonisti in uporaba za moduliranje imunskega sistema
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
EP1603585A2 (fr) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine
EP1642135A1 (fr) * 2003-06-06 2006-04-05 AstraZeneca AB Methode de diagnostic de maladies inflammatoires intestinales
EP2289908B1 (fr) 2003-07-11 2013-08-07 Evotec International GmbH Utilisation de produits des protéines DG177 sécretées pour la prévention et le traitement de maladies du pancreas et/ou de l'obésité et/ou du syndrome métabolique
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
CN102517381A (zh) 2003-10-07 2012-06-27 千年药品公司 用于鉴定、评价、预防和治疗卵巢癌的核酸分子和蛋白质
AU2004316290C1 (en) 2003-11-06 2012-02-02 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005054864A2 (fr) * 2003-11-22 2005-06-16 Bayer Healthcare Ag Diagnostic et traitements therapeutiques des maladies associees a l'element 1 de la sous-famille k du canal potassique (kcnk1)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP2005230011A (ja) 2004-02-20 2005-09-02 Samsung Electronics Co Ltd 乳ガン関連蛋白質、それをコーディングする遺伝子、及び該蛋白質及び該遺伝子を利用した乳ガンの診断方法
JP2005314397A (ja) * 2004-03-31 2005-11-10 Mitsubishi Chemicals Corp 抗コンドロモジュリン−１特異的抗体及びその利用
JPWO2005097204A1 (ja) * 2004-04-09 2008-02-28 武田薬品工業株式会社 癌の予防・治療剤
JP5234734B2 (ja) 2004-06-01 2013-07-10 ジェネンテック， インコーポレイテッド 抗体−薬物結合体および方法
CA2565524A1 (fr) * 2004-06-04 2005-12-15 Applied Research Systems Ars Holding N.V. Variante d'epissage de unc5h2
US20060024677A1 (en) * 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
US20090004193A1 (en) * 2004-07-23 2009-01-01 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Vasoactive Intestinal Peptide Receptor 1 (Vpac1)
US20090214517A1 (en) * 2004-07-27 2009-08-27 Justin Wong Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
DE102004045705A1 (de) 2004-09-21 2006-04-06 B.R.A.H.M.S Ag Verwendungen der Carbamoylphosphat Synthetase 1(CPS) als humoraler Biomarker für die Diagnose von Tumorerkrankungen und chronisch entzündlichen Darmerkrankungen
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006053442A1 (fr) * 2004-11-22 2006-05-26 Diagnocure Inc. Cible specifique et sensible (calml3) pour un diagnostic, un pronostic et/ou une therapie adaptee au diagnostic et au savoir-faire du domaine, d'un cancer du poumon
WO2006060533A2 (fr) 2004-12-01 2006-06-08 Genentech, Inc. Conjugues medicament anticorps et procedes correspondants
WO2006090389A2 (fr) * 2005-02-24 2006-08-31 Compugen Ltd. Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes
WO2006090810A2 (fr) 2005-02-25 2006-08-31 Oncotherapy Science, Inc. Vaccins a base de peptides pour cancers du poumon exprimant des polypeptides ttk, urlc10 ou koc1
US8206705B2 (en) 2005-03-02 2012-06-26 Biogen Idec Ma Inc. KIM-1 antibodies for treatment of TH2-mediated conditions
WO2006107259A1 (fr) * 2005-04-07 2006-10-12 Astrazeneca Ab Procede pour l’evaluation de la predisposition et/ou de la susceptibilite a la bpco au moyen de l’analyse de fgf-bp1
CN114921544A (zh) * 2005-04-15 2022-08-19 Epi基因组股份公司 分析细胞增殖性病症的方法和核酸
EP1869222A4 (fr) * 2005-04-15 2010-01-20 Oncomethylome Sciences S A Marqueur de méthylation pour le diagnostic et le traitement des cancers
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
WO2006118308A1 (fr) 2005-05-02 2006-11-09 Toray Industries, Inc. Composition et procede permettant de diagnostiquer un cancer esophagien et une metastase d’un cancer esophagien
US7910552B2 (en) 2005-05-27 2011-03-22 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof
ES2406063T3 (es) 2005-12-08 2013-06-05 Medarex, Inc. Anticuerpos monoclonales humanos contra la proteína Tirosina Quinasa 7(PTK7) y su uso
CA2646611A1 (fr) 2006-03-21 2008-05-22 Genentech, Inc. Therapies combinatoires
WO2007115213A2 (fr) * 2006-03-30 2007-10-11 Epigenomics Ag Méthodes et acides nucléiques pour des analyses de troubles prolifératifs cellulaires
CA2649777C (fr) * 2006-04-17 2018-08-14 Epigenomics Ag Procedes et acides nucleiques pour detecter des troubles de proliferation de cellules colorectales
US20100184027A1 (en) * 2006-07-13 2010-07-22 Epigenomics Ag Methods and nucleic acids for analyses of cellular proliferative disorders
EP1932854A1 (fr) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides s'apparentant à une protéine de membrane associée à un lysosome (LAMP), ligands correspondants et leur utilisation dans le cadre de la détection et de la purification de cellules dendritiques plasmacytoïdes humaines
WO2008104803A2 (fr) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Protéines
WO2008104805A2 (fr) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Protéines
UA101810C2 (ru) 2007-07-27 2013-05-13 Имматикс Биотекнолоджис Гмбх Новые методы иммунотерапии в лечении нейрональных опухолей и опухолей головного мозга
AU2012244137B2 (en) * 2007-07-27 2015-06-11 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumours
MX2010001086A (es) 2007-07-27 2010-04-09 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra tumores neuronales y cerebrales.
WO2009032292A1 (fr) 2007-09-06 2009-03-12 Case Western Reserve University Procédés de diagnostic et de traitement de cancers
RU2490277C2 (ru) 2007-09-26 2013-08-20 Дженентек, Инк. Новые антитела
DK2245052T3 (en) 2008-01-25 2017-09-11 Univ Aarhus SELECTIVE EXOSITE INHIBITATION OF PAPP-A ACTIVITY AGAINST IGFBP-4
RS53872B2 (sr) * 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
KR20110034602A (ko) 2008-05-21 2011-04-05 도레이 카부시키가이샤 식도암 판정용 조성물 및 방법
NZ589806A (en) * 2008-05-30 2012-08-31 Curis Inc Variant hedgehog-interacting protein (hhip1) and methods and uses thereof
EP2303332B1 (fr) 2008-07-15 2014-12-31 Genentech, Inc. Conjugués de dérivés d anthracycline, procédé de préparation associé et utilisation comme composés antitumoraux
EP2568044B1 (fr) 2008-09-29 2015-04-08 The Trustees of The University of Pennsylvania Vaccins ciblés sur un marqueur vasculaire tumoral
SG10201609416XA (en) 2009-03-25 2016-12-29 Genentech Inc NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
SG176947A1 (en) 2009-07-03 2012-01-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
KR101961495B1 (ko) 2009-12-23 2019-03-22 아비펩 피티와이 리미티트 면역-컨쥬게이트 및 그 제조방법 ２
EA024730B1 (ru) 2010-04-15 2016-10-31 Медимьюн Лимитед Пирролбензодиазепиновые соединения, их конъюгаты, фармацевтические композиции, содержащие указанные конъюгаты, и применение указанных конъюгатов
CN107335062B (zh) 2010-06-08 2021-09-24 基因泰克公司 半胱氨酸改造的抗体和偶联物
KR102166408B1 (ko) 2010-09-29 2020-10-16 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
WO2012142662A1 (fr) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Molécules à domaine variable modifié et procédés de préparation et d'utilisation de celles-ci
EP2707723B1 (fr) 2011-05-12 2016-02-10 Genentech, Inc. Procédé lc-ms/ms de surveillance de réactions multiples pour détecter des anticorps thérapeutiques dans des échantillons animaux à l'aide de peptides de signature d'infrastructure
WO2013045464A1 (fr) * 2011-09-26 2013-04-04 Roche Diagnostics Gmbh Biomarqueurs d'adnc dans du sang total pour l'évaluation du cancer colorectal
BR112014009050B1 (pt) 2011-10-14 2022-06-21 Medimmune Limited Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
HUE036243T2 (hu) 2012-08-31 2018-06-28 Vasculead Inc PSF1-származék peptid
CN105102068B (zh) 2012-10-12 2018-06-01 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗体结合物
CA2887899C (fr) 2012-10-12 2020-03-31 Adc Therapeutics Sarl Conjugues anticorps anti-cd22 - pyrrolobenzodiazepine
CA2887894C (fr) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Conjugues anticorps anti-psma - pyrrolobenzodiazepine
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
EP2766048B1 (fr) 2012-10-12 2014-12-10 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
CA2901941C (fr) 2013-03-13 2020-04-07 Spirogen Sarl Pyrrolobenzodiazepines et leurs conjugues
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2918139A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugues anticorps-medicament dimerique 1-(chloromethyl)-2,3-dihydro-1 h-benzo [e]indole, et methodes d'utilisation et de traitement
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
PE20160561A1 (es) 2013-10-11 2016-06-03 Oxford Biotherapeutics Ltd Anticuerpos conjugados contra ly75 para el tratamiento de cancer
MX2016007578A (es) 2013-12-16 2016-10-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
SG11201604905WA (en) 2013-12-16 2016-07-28 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
RU2017107502A (ru) 2014-09-12 2018-10-12 Дженентек, Инк. Антитела и конъюгаты, сконструированные введением цистеина
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
WO2016083468A1 (fr) 2014-11-25 2016-06-02 Adc Therapeutics Sa Conjugués anticorps-pyrrolobenzodiazépine
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (fr) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Conjugués anticorps-protac et procédés d'utilisation
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
EP3522933B1 (fr) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Procédés de préparation de conjugués anticorps-médicament
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
HUE054689T2 (hu) 2017-02-08 2021-09-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018192944A1 (fr) 2017-04-18 2018-10-25 Medimmune Limited Conjugués de pyrrolobenzodiazépine
KR20190141666A (ko) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 항-axl 항체-약물 접합체로의 병용 요법
WO2018229222A1 (fr) 2017-06-14 2018-12-20 Adc Therapeutics Sa Régimes posologiques pour l'administration d'un cam anti-cd19
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
KR20220156974A (ko) 2017-09-20 2022-11-28 주식회사 피에이치파마 타일란스타틴 유사체
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (zh) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 缀合的化学降解诱导剂及使用方法
IL283522B2 (en) 2018-12-03 2025-03-01 Agensys Inc Pharmaceutical compositions containing anti-191P4D12 antibody drug conjugates and methods of using them
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
CN112083168A (zh) * 2019-06-14 2020-12-15 复旦大学附属华山医院 多肽段诊断模型及其在预测髓母细胞瘤转移风险中的应用
CN110819714B (zh) * 2019-11-22 2023-01-10 南方医科大学深圳医院 一种抑癌基因及其应用
CN114350640B (zh) * 2019-12-13 2023-09-08 中国科学院天津工业生物技术研究所 一株表达几丁质酶重组菌的构建及高酶活突变体的筛选
CN111748623B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 肝癌患者是否复发的预测标志物及试剂盒
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4426727A2 (fr) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
CN114966062B (zh) * 2022-07-29 2022-09-30 北京大学第三医院（北京大学第三临床医学院） 用于预测抗mda5抗体阳性皮肌炎合并间质性肺病的分子标记物及其应用
TW202432187A (zh) 2022-12-23 2024-08-16 美商建南德克公司 小腦蛋白降解劑結合物及其用途
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
WO2003042661A2 (fr) 2003-05-22
WO2003042661A3 (fr) 2004-10-28

Similar Documents

Publication Publication Date Title
WO2003042661A3 (fr) Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
WO2002059377A3 (fr) Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
WO2004073657A3 (fr) Methode de diagnostic du cancer, composition et methodes de criblage destinees a identifier des modulateurs du cancer
WO2003003906A3 (fr) Procede de diagnostic du cancer de la vessie, compositions et procedes de criblage de modulateurs du cancer de la vessie
WO2002102235A3 (fr) Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
WO2004048938A3 (fr) Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous
WO2004113571A3 (fr) Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
WO2002030268A3 (fr) Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
EP2258872A3 (fr) Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2004063355A3 (fr) Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
WO2005047534A3 (fr) Procedes et compositions de prediction de reponse de la neoplasie maligne a un traitement
EP2267454A3 (fr) Diagnostic et traitement de l'invasion des cellules cancéreuses
EP1365034A3 (fr) Procédés et compositions pour la prédiction, le diagnostic, le pronostic, la prévention et le traitement de neoplasie maligne
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
DE60028970D1 (de) An her2 bindende peptidverbindungen
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2003079982A3 (fr) Amplification de genes en cas de cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2006027693A8 (fr) Genes et arn variants specifiques de tumeur et leurs utilisations comme cibles pour le traitement et le diagnostic du cancer
WO2003013431A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein
WO2004003166A3 (fr) Anticorps et leurs applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 21/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "60/355,250"

Free format text: IN PCT GAZETTE 21/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "60/355,250"

WWE Wipo information: entry into national phase

Ref document number: 2002792272

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2467433

Country of ref document: CA

Ref document number: 2003544445

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002792272

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002792272

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载